| Drug / Therapy | First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes |
| Indication | — |
| Decision Type | Early Phase 1 |
| Trial Phase | Early Phase 1 |
| ClinicalTrials.gov | NCT06239636 |
Sana Biotechnology (SANA) operates in the Cell Engineering sector. The current BTS Score is 41 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Early Phase 1 date for First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes by Sana Biotechnology (SANA) is scheduled for May 1, 2025. This is the target date for the FDA to make a decision on this application.
First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes is being developed by Sana Biotechnology for the treatment of its target indication. It is currently in Early Phase 1 clinical trials.
If First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes receives FDA approval, Sana Biotechnology (SANA) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Early Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for SANA on DilutionWatch at dilutionwatch.com/stock/SANA.html.
You can view the full BiotechSigns company profile for Sana Biotechnology (SANA) at biotechsign.com/app/company/SANA, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.